[go: up one dir, main page]

FR2774591B1 - Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie - Google Patents

Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie

Info

Publication number
FR2774591B1
FR2774591B1 FR9801709A FR9801709A FR2774591B1 FR 2774591 B1 FR2774591 B1 FR 2774591B1 FR 9801709 A FR9801709 A FR 9801709A FR 9801709 A FR9801709 A FR 9801709A FR 2774591 B1 FR2774591 B1 FR 2774591B1
Authority
FR
France
Prior art keywords
fibrate
metformin
medicines
association
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR9801709A
Other languages
English (en)
Other versions
FR2774591A1 (fr
Inventor
Yves Bonhomme
Philippe Briet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sante SAS
Original Assignee
LIPHA SAS
LIPHA Liyonnaise Industrielle Pharmaceutique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR9801709A priority Critical patent/FR2774591B1/fr
Application filed by LIPHA SAS, LIPHA Liyonnaise Industrielle Pharmaceutique filed Critical LIPHA SAS
Priority to SI9930017T priority patent/SI1054665T1/xx
Priority to DK99910169T priority patent/DK1054665T3/da
Priority to UA2000095172A priority patent/UA70315C2/uk
Priority to ES99910169T priority patent/ES2162517T3/es
Priority to KR1020007008836A priority patent/KR100567608B1/ko
Priority to PT81108560T priority patent/PT1054665E/pt
Priority to CZ20002828A priority patent/CZ290101B6/cs
Priority to HU0100801A priority patent/HU224619B1/hu
Priority to SK1156-2000A priority patent/SK283212B6/sk
Priority to BR9907866A priority patent/BRPI9907866B8/pt
Priority to AU29233/99A priority patent/AU746821B2/en
Priority to HK01105732.1A priority patent/HK1034913B/xx
Priority to IDW20001765A priority patent/ID26254A/id
Priority to US09/601,618 priority patent/US6372790B1/en
Priority to AT99910169T priority patent/ATE204754T1/de
Priority to CA002320039A priority patent/CA2320039C/fr
Priority to DE69900249T priority patent/DE69900249T2/de
Priority to EP99910169A priority patent/EP1054665B1/fr
Priority to PL342665A priority patent/PL196874B1/pl
Priority to CNB998029041A priority patent/CN1151785C/zh
Priority to RU2000123567/14A priority patent/RU2207850C2/ru
Priority to JP2000531156A priority patent/JP4767411B2/ja
Priority to PCT/EP1999/000614 priority patent/WO1999040904A2/fr
Priority to MYPI99000445A priority patent/MY118164A/en
Priority to ZA9901077A priority patent/ZA991077B/xx
Priority to TW088102063A priority patent/TW518222B/zh
Priority to ARP990100598A priority patent/AR018286A1/es
Publication of FR2774591A1 publication Critical patent/FR2774591A1/fr
Application granted granted Critical
Publication of FR2774591B1 publication Critical patent/FR2774591B1/fr
Priority to NO20004056A priority patent/NO328314B1/no
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR9801709A 1998-02-12 1998-02-12 Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie Expired - Lifetime FR2774591B1 (fr)

Priority Applications (29)

Application Number Priority Date Filing Date Title
FR9801709A FR2774591B1 (fr) 1998-02-12 1998-02-12 Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie
DE69900249T DE69900249T2 (de) 1998-02-12 1999-01-30 Pharmazeutische zusammensetzung von metformin und fibrat, und ihre verwendung zur behandlung von hyperglykämie
UA2000095172A UA70315C2 (en) 1998-02-12 1999-01-30 Pharmaceutical composition comprising metformin anpharmaceutical composition comprising metformin and fibrate useful for formulations intended for lowd fibrate useful for formulations intended for lowering hyperglycemia ering hyperglycemia
ES99910169T ES2162517T3 (es) 1998-02-12 1999-01-30 Composicion farmaceutica que comprende una combinacion de metformin y fibrato y su uso en la preparacion de medicamentos destinados a reducir la hiperglicemia.
KR1020007008836A KR100567608B1 (ko) 1998-02-12 1999-01-30 메트포르민과 피브레이트의 조합물로 이루어진 약학조성물, 및 과혈당증 저하용 약제의 제조 용도
PT81108560T PT1054665E (pt) 1998-02-12 1999-01-30 Composicao farmaceutica compreendendo uma combinacao de metformina e fibrato e seu uso no tratamento da hiperglicemia
CZ20002828A CZ290101B6 (cs) 1998-02-12 1999-01-30 Farmaceutický prostředek sestávající z kombinace metforminu a fibrátu a jeho použití k přípravě léčiv určených ke snižování hyperglykémie
HU0100801A HU224619B1 (hu) 1998-02-12 1999-01-30 Metformin és fibrát kombinációját tartalmazó gyógyászati készítmények és ezek alkalmazása kórosan magas vércukorszint csökkentését célzó gyógyszerek előállítására
SK1156-2000A SK283212B6 (sk) 1998-02-12 1999-01-30 Farmaceutický prostriedok pozostávajúci z kombinácie metformínu a fibrátu a jeho použitie na znižovanie hyperglykémie
BR9907866A BRPI9907866B8 (pt) 1998-02-12 1999-01-30 composição farmacêutica, bem como seu uso
AU29233/99A AU746821B2 (en) 1998-02-12 1999-01-30 Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the preparation of medicines intended to reduce hyperglycaemia
HK01105732.1A HK1034913B (en) 1998-02-12 1999-01-30 Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the preparation of medicines intended to reduce hyperglycaemia
IDW20001765A ID26254A (id) 1998-02-12 1999-01-30 Komposisi farmasi yang terdiri dari satu gabungan antara metformin dan fibrate, dan penggunaannya dalam penyiapan obat-obatan yang ditujukan untuk menurukan hiperglikaemia
US09/601,618 US6372790B1 (en) 1998-02-12 1999-01-30 Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the preparation of medicines intended to reduce hyperglycaemia
SI9930017T SI1054665T1 (en) 1998-02-12 1999-01-30 Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the treatment of hyperglycemia
CA002320039A CA2320039C (fr) 1998-02-12 1999-01-30 Composition pharmaceutique comprenant une combinaison de metformine et de fibrate, et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie
PL342665A PL196874B1 (pl) 1998-02-12 1999-01-30 Preparat farmaceutyczny zawierający metforminę i fibrat oraz zastosowanie metforminy i fibratu do otrzymywania preparatu leczniczego do obniżania poziomu glukozy we krwi
DK99910169T DK1054665T3 (da) 1998-02-12 1999-01-30 Farmaceutisk præparat omfattende en kombination af metformin og fibrat og anvendelse deraf til fremstilling af medikamenter beregnet til at reducere hyperglykæmi
EP99910169A EP1054665B1 (fr) 1998-02-12 1999-01-30 Composition pharmaceutique comprenant une combinaison de metformine et de fibrate, et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie
CNB998029041A CN1151785C (zh) 1998-02-12 1999-01-30 含有二甲双胍和贝特联合的药物组合物及其在制备降低高血糖药物中的应用
RU2000123567/14A RU2207850C2 (ru) 1998-02-12 1999-01-30 Фармацевтическая композиция, содержащая в комбинации метформин и фибрат, и ее применение при приготовлении лекарственных средств, предназначенных для снижения гипергликемии
JP2000531156A JP4767411B2 (ja) 1998-02-12 1999-01-30 メトホルミンおよびフィブラートとの組み合わせからなる医薬組成物と、高血糖症を緩和するための医薬品製造へのその使用
PCT/EP1999/000614 WO1999040904A2 (fr) 1998-02-12 1999-01-30 Composition pharmaceutique comprenant une combinaison de metformine et de fibrate, et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie
AT99910169T ATE204754T1 (de) 1998-02-12 1999-01-30 Pharmazeutische zusammensetzung von metformin und fibrat, und ihre verwendung zur behandlung von hyperglykämie
MYPI99000445A MY118164A (en) 1998-02-12 1999-02-09 Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the preparation of medicines intended to reduce hyperglycaemia
ZA9901077A ZA991077B (en) 1998-02-12 1999-02-10 Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the preparation of medicines intended to reduce hyperglycaemia.
TW088102063A TW518222B (en) 1998-02-12 1999-02-10 Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the preparation of medicines intended to reduce hyperglycaemia
ARP990100598A AR018286A1 (es) 1998-02-12 1999-02-12 Composicion farmaceutica que en calidad de principio activo contiene la asociacion de metformina y fibrato, y la utilizacion de esta asociacion para preparar medicamentos
NO20004056A NO328314B1 (no) 1998-02-12 2000-08-11 Farmasoytisk preparat som omfatter en kombinasjon av metformin og fibrat, og dets anvendelse til fremstilling av medisiner beregnet til a redusere hyperglykemi

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9801709A FR2774591B1 (fr) 1998-02-12 1998-02-12 Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie

Publications (2)

Publication Number Publication Date
FR2774591A1 FR2774591A1 (fr) 1999-08-13
FR2774591B1 true FR2774591B1 (fr) 2000-05-05

Family

ID=9522912

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9801709A Expired - Lifetime FR2774591B1 (fr) 1998-02-12 1998-02-12 Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie

Country Status (27)

Country Link
US (1) US6372790B1 (fr)
EP (1) EP1054665B1 (fr)
JP (1) JP4767411B2 (fr)
KR (1) KR100567608B1 (fr)
CN (1) CN1151785C (fr)
AR (1) AR018286A1 (fr)
AT (1) ATE204754T1 (fr)
AU (1) AU746821B2 (fr)
BR (1) BRPI9907866B8 (fr)
CA (1) CA2320039C (fr)
CZ (1) CZ290101B6 (fr)
DE (1) DE69900249T2 (fr)
DK (1) DK1054665T3 (fr)
ES (1) ES2162517T3 (fr)
FR (1) FR2774591B1 (fr)
HU (1) HU224619B1 (fr)
ID (1) ID26254A (fr)
MY (1) MY118164A (fr)
NO (1) NO328314B1 (fr)
PL (1) PL196874B1 (fr)
PT (1) PT1054665E (fr)
RU (1) RU2207850C2 (fr)
SK (1) SK283212B6 (fr)
TW (1) TW518222B (fr)
UA (1) UA70315C2 (fr)
WO (1) WO1999040904A2 (fr)
ZA (1) ZA991077B (fr)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2216335T3 (es) * 1997-12-08 2004-10-16 Bristol-Myers Squibb Company Nuevas sales de metformina y procedimiento.
US6982281B1 (en) 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
FR2796551B1 (fr) * 1999-07-23 2003-07-25 Lipha Nouveaux sels de metformine, leur procede d'obtention et les compositions pharmaceutiques en renfermant
FR2796940B1 (fr) * 1999-07-26 2005-04-08 Lipha Nouveaux sels de metformine, leur procede d'obtention et les compositions pharmaceutiques en renfermant
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
US7151191B2 (en) * 2000-01-13 2006-12-19 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6531158B1 (en) * 2000-08-09 2003-03-11 Impax Laboratories, Inc. Drug delivery system for enhanced bioavailability of hydrophobic active ingredients
JP4829411B2 (ja) * 2001-02-23 2011-12-07 キッセイ薬品工業株式会社 Ｃ型慢性肝炎治療剤
GB0119480D0 (en) 2001-08-09 2001-10-03 Jagotec Ag Novel compositions
US8911781B2 (en) 2002-06-17 2014-12-16 Inventia Healthcare Private Limited Process of manufacture of novel drug delivery system: multilayer tablet composition of thiazolidinedione and biguanides
EP1424070A1 (fr) * 2002-11-28 2004-06-02 Fournier Laboratories Ireland Limited Combinaison d'un agoniste de PPAR-alpha et de metformine pour la réduction du taux de triglycérides sériques
WO2004054549A1 (fr) 2002-12-13 2004-07-01 Jagotec Ag Preparation topique de spironolactone nanoparticulaire
BRPI0407303A (pt) * 2003-02-07 2006-02-07 Ajinomoto Kk Composição farmacêutica
FR2851734B1 (fr) * 2003-02-28 2006-06-09 Galenix Innovations Procede pour la fabrication d'une composition pharmaceutique sous la forme de comprimes contenant un fibrate et comprimes obtenus selon le procede
FR2858556B1 (fr) * 2003-08-06 2006-03-10 Galenix Innovations Composition pharmaceutique solide dispersible et/ou orodispersible non pelliculee contenant au moins le principe actif metformine, et procede de preparation
RU2241449C1 (ru) * 2003-09-25 2004-12-10 Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" Фармацевтическая композиция для лечения диабета (варианты)
US8062664B2 (en) * 2003-11-12 2011-11-22 Abbott Laboratories Process for preparing formulations of lipid-regulating drugs
JP4845740B2 (ja) 2003-12-19 2011-12-28 オメガ バイオ‐ファーマ（アイ．ピー．３）リミテッド 糖尿病を治療するための組成物および方法
EP1559419A1 (fr) * 2004-01-23 2005-08-03 Fournier Laboratories Ireland Limited Composition pharmaceutique contenant une combinaison de mefformine et d'un fibrate et les procédés pour les obtenir
EP1714648A4 (fr) * 2004-02-09 2010-05-26 Aska Pharm Co Ltd Medicament de combinaison
EP1591114A1 (fr) * 2004-03-12 2005-11-02 Fournier Laboratories Ireland Limited Utilisation de la metformine et de l'Orlistat pour le traitement ou la prévention de l'obésité
US20060286182A1 (en) * 2005-06-21 2006-12-21 Abeille Pharmaceuticals, Inc. Synergistic cinnamon combinations and methods for enhancing insulin activity
GB0602639D0 (en) * 2006-02-09 2006-03-22 Novartis Ag Organic compounds
CA2657394A1 (fr) 2006-08-04 2008-02-07 Aska Pharmaceutical Co., Ltd. Preparation contenant un agent du type fibrate et methode de production connexe
CN101342164B (zh) * 2007-08-21 2011-04-20 阜新市仙鹤制药有限责任公司 苯扎贝特控释制剂及其制备方法
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US9339458B2 (en) * 2009-02-18 2016-05-17 Itf Research Pharma, S.L.U. Use of vaginal insulin sensitizing agents
ES2344183B1 (es) * 2009-02-18 2011-06-10 Italfarmaco, S.A. Uso de agentes sensibilizantes a insulina por via vaginal.
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
JP2012171911A (ja) 2011-02-22 2012-09-10 Kao Corp Ｐｐａｒ活性化剤
IN2015KN00076A (fr) * 2012-07-10 2015-07-31 Thetis Pharmaceuticals Llc
US8765811B2 (en) * 2012-07-10 2014-07-01 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US9382187B2 (en) * 2012-07-10 2016-07-05 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US9505709B2 (en) 2014-05-05 2016-11-29 Thetis Pharmaceuticals Llc Compositions and methods relating to ionic salts of peptides
WO2015183794A1 (fr) 2014-05-27 2015-12-03 City Of Hope Complexes d'agonistes de tgr5 pour le traitement du diabète et du cancer
US9242008B2 (en) 2014-06-18 2016-01-26 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of fatty acids
MX2016016830A (es) 2014-06-18 2017-07-07 Thetis Pharmaceuticals Llc Complejos de aminoacidos minerales de agentes activos.
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
FR3050112B1 (fr) * 2016-04-15 2020-09-04 Soc Civ Immobiliere Gecinq Utilisation de l'acide fenofibrique dans le traitement des maladies hepatiques
EP3454907B1 (fr) 2016-06-03 2020-07-22 Thetis Pharmaceuticals LLC Compositions et méthodes en lien avec des sels de médiateurs
WO2018058109A1 (fr) * 2016-09-26 2018-03-29 Nusirt Sciences, Inc. Compositions et méthodes pour le traitement de troubles métaboliques
FR3056908B1 (fr) * 2016-09-30 2019-04-19 Nashpharm Sel de metformine et d'elafibranor presentant une activite duale pour le traitement de l'obesite associee a la steato-hepatite non alcoolique (nash) et a l'hypertriglyceridemie
CA3078723A1 (fr) 2016-11-28 2018-05-31 Nachiappan Chidambaram Traitement oral a base d'undecanoate de testosterone
US12150945B2 (en) 2018-07-20 2024-11-26 Lipocine Inc. Liver disease
GB2599950A (en) * 2020-10-16 2022-04-20 Zentiva Ks Pharmaceutical compositions with low amounts of nitrosamine impurities and methods for producing the same
WO2023119100A1 (fr) * 2021-12-22 2023-06-29 Mankind Pharma Ltd. Compositions pharmaceutiques stables

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4080472A (en) 1974-03-22 1978-03-21 Societe D'etudes Et D'exploitation De Marques Et Brevets S.E.M.S. Metformin 2-(p-chlorophenoxy)-2-methylpropionate
FR2264525B1 (fr) * 1974-03-22 1977-11-04 Expl Marques Brevets Et
DE3729209A1 (de) * 1987-09-01 1989-03-09 Boehringer Mannheim Gmbh Verwendung von bezafibrat zur behandlung von diabetes
ZA918168B (en) * 1990-10-16 1993-04-14 Takeda Chemical Industries Ltd Prolonged release preparation and polymers thereof.
JP3852621B2 (ja) * 1992-01-21 2006-12-06 あすか製薬株式会社 血管内皮細胞機能改善剤
EP0930882A2 (fr) * 1996-08-02 1999-07-28 Institut Pasteur De Lille Prevention ou traitement de diabetes non insulinodependants ou de maladies cardiovasculaires avec des modulateurs ppar

Also Published As

Publication number Publication date
BRPI9907866B1 (pt) 2017-08-15
RU2207850C2 (ru) 2003-07-10
PL342665A1 (en) 2001-07-02
DK1054665T3 (da) 2001-12-27
EP1054665B1 (fr) 2001-08-29
CZ290101B6 (cs) 2002-05-15
WO1999040904A2 (fr) 1999-08-19
HUP0100801A2 (hu) 2001-08-28
PT1054665E (pt) 2002-02-28
JP4767411B2 (ja) 2011-09-07
ATE204754T1 (de) 2001-09-15
WO1999040904A3 (fr) 1999-09-30
JP2002502869A (ja) 2002-01-29
HUP0100801A3 (en) 2001-12-28
HU224619B1 (hu) 2005-11-28
SK11562000A3 (sk) 2000-12-11
EP1054665A2 (fr) 2000-11-29
NO328314B1 (no) 2010-01-25
KR20010040925A (ko) 2001-05-15
US6372790B1 (en) 2002-04-16
BRPI9907866B8 (pt) 2021-05-25
AU746821B2 (en) 2002-05-02
NO20004056D0 (no) 2000-08-11
AR018286A1 (es) 2001-11-14
DE69900249T2 (de) 2002-06-13
MY118164A (en) 2004-09-30
ID26254A (id) 2000-12-07
CA2320039C (fr) 2008-07-22
SK283212B6 (sk) 2003-03-04
CA2320039A1 (fr) 1999-08-19
NO20004056L (no) 2000-08-11
CZ20002828A3 (cs) 2000-11-15
DE69900249D1 (de) 2001-10-04
UA70315C2 (en) 2004-10-15
HK1034913A1 (en) 2001-11-09
BR9907866A (pt) 2000-10-31
ES2162517T3 (es) 2001-12-16
ZA991077B (en) 1999-08-11
AU2923399A (en) 1999-08-30
CN1151785C (zh) 2004-06-02
CN1290160A (zh) 2001-04-04
TW518222B (en) 2003-01-21
KR100567608B1 (ko) 2006-04-04
PL196874B1 (pl) 2008-02-29
FR2774591A1 (fr) 1999-08-13

Similar Documents

Publication Publication Date Title
FR2774591B1 (fr) Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie
FR2734483B1 (fr) Forme d'administration pharmaceutique comprenant de l'oxybutynine
FR11C0007I2 (fr) Composition pharmaceutique stabilisee a l'aide d'un agent de base
EP0788359A4 (fr) Compositions utiles a la preparation de medicaments destines au traitement de divers troubles refractaires
AU6379294A (en) Nasal pharmaceutical composition containing a progestational agent
ATE206924T1 (de) Oral anzuwendende arzneizubereitung enthaltend olanzapin
AU4344296A (en) Use of mono and bicarboxylic acid amides for the manufacture of a medicament active at the peripheral cannabinoid receptor
FR2761265B1 (fr) Composition pharmaceutique pour l'administration orale d'un derive du n-piperidino-3-pyrazolecarboxamide, de ses sels et de leurs solvates
FR2732223B1 (fr) Composition pharmaceutique pour administration transdermique
DZ2494A1 (fr) Composition pharmaceutique d'oméprazole.
ATE178489T1 (de) Fluessige oral anzuwendende arzneizubereitungen enthaltend paroxetinresinate
FI955691L (fi) Lipoproteiini(a):ta alentava aine, kolesterolia alentava aine ja näitä aineita sisältävät lääkkeet
HUP9900348A3 (en) New oxazolidinone derivatives, preparation and use thereof and medicaments containing these compounds
FI935617A7 (fi) 3,5-substituoituja aminobentsoyyliguanidiineja, menetelmä niiden valmistamiseksi, niiden käyttö lääkkeinä tai diagnostisina aineina sekä niitä sisältävä lääke
ITMI930582A0 (it) Composizione farmeceutiche ad attivita' analgesica
IL112745A0 (en) Formulations for orally administered pharmaceutical agents
ITMI931325A1 (it) Composizione farmaceutica ad attivita' analgesica
FR2732217B1 (fr) Forme d'administration solide a usage oral
EE05317B1 (et) Etinl”stradiooli ja drospirenooni sisaldav farmatseutiline kompositsioon kasutamiseks rasestumisvastase vahendina
FR2714603B1 (fr) Composition dermatologique et son utilisation pour la préparation d'un médicament.
FR2723317B1 (fr) Utilisation d'antagonistes de la neurotensine pour la preparation de medicaments diuretiques
ZA935199B (en) 3- And 5-substituted 1,2,3,4-oxatriazole-5-imine compounds a process for the preparation thereof a pharmaceutical preparation containing said compounds and the use of said compounds for the preparation of medicaments
FR2698544B1 (fr) Composition pharmaceutique topique pour allergies respiratoires.
IL116596A0 (en) 8-oxo-5, 8 dihydro-6h-dibenzo (a,g)quinolizine-13-propanoic acid derivatives their preparation and their therapeutic application
FR2746012B1 (fr) Utilisation de la tiamuline pour la preparation d'un medicament comme agent de reversion de la multichimioresistance cancereuse

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 19

PLFP Fee payment

Year of fee payment: 20